Neuroectodermal and Neuroendocrine Tumors

Neuroectodermal and Neuroendocrine Tumors arise from primitive neural crest cells or neuroendocrine cells distributed throughout the body. This category covers neuroectodermal tumors, neuroendocrine tumors, and brain tumor cell lines. Our portfolio includes neuroblastoma cell lines (e.g., SH-SY5Y, SK-N-BE, IMR-32, NGP, LAN-5) for pediatric cancer research; these are derived from the sympathetic nervous system and often have MYCN amplification. Neuroblastoma cell lines are used for studying differentiation (retinoic acid), apoptosis, and drug resistance. Glioblastoma cell lines (e.g., U87, U251, T98G, LN229, A172, U118) model aggressive brain tumors; they are used for temozolomide resistance, invasion assays, and intracranial xenograft models. Glioblastoma cell lines often have EGFR amplification, PTEN loss, or IDH1 mutations. Medulloblastoma cell lines (e.g., DAOY, D283, D341, ONS-76) are cerebellar primitive neuroectodermal tumors (PNETs); they are used for studies on Sonic Hedgehog (SHH) and WNT pathways. Astrocytoma cell lines (e.g., SW1783, CCF-STTG1, U373) represent lower-grade gliomas (grade II-III); they are used for studies on p53 and IDH mutations. Oligodendroglioma cell lines (e.g., HOG, TC620, KG-1-C) are rare; they are used for studies on 1p/19q codeletion and IDH mutations. Ependymoma cell lines (e.g., BXD-1425, EPND, EPC) are derived from ependymal cells lining the ventricles; they are used for studies on RELA fusions and spinal cord tumors. Schwannoma cell lines (e.g., HEI-193, sNF96.2, SNF-1) come from peripheral nerve sheath tumors (vestibular schwannoma, neurofibroma); they are used for studies on NF2 mutations and schwannomin. Meningioma cell lines (e.g., CH157, IOMM-Lee, KT21, SF-3061) are typically benign but can be malignant; they are used for studies on NF2, TRAF7, and SMO mutations. Pheochromocytoma cell line (PC12) is derived from rat adrenal medulla and is widely used for neurosecretion studies, neurite outgrowth (NGF-induced), and catecholamine synthesis. Neuroendocrine carcinoma lines (e.g., BON-1 for pancreatic NET, NCI-H727 for lung carcinoid, QGP-1 for somatostatinoma) are used for studies on somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Merkel cell carcinoma lines (e.g., MKL-1, MCPV-positive, WaGa, MCC13) are rare skin neuroendocrine cancers associated with Merkel cell polyomavirus (MCPyV); they are used for immunotherapy and chemotherapy studies. Neuroectodermal tumor (PNET) lines include primitive neuroectodermal tumor (PNET) (e.g., TC-71, SK-N-MC, CHP-100, EW-7) which are Ewing’s sarcoma family tumors; they have EWSR1-ETS fusions. Retinoblastoma cell lines (e.g., Y79, WERI-Rb-1, SO-Rb50) are ocular PNETs with RB1 mutations; they are used for studies on retinoblastoma protein and gene therapy. Olfactory neuroblastoma (esthesioneuroblastoma) lines (e.g., JARC, MZ-1, FEV-1) are rare sinonasal tumors; they are used for studies on olfactory differentiation and chemotherapy. Ganglioneuroblastoma is a transitional tumor between ganglioneuroma and neuroblastoma; cell lines include GOTO and NB-1. Neuroendocrine prostate cancer (NEPC) lines (e.g., NCI-H660, LNCaP-derived NE models, PDX-derived lines) represent aggressive variant with loss of androgen receptor expression and gain of neuroendocrine markers (chromogranin A, synaptophysin).

Researchers use neuroblastoma cell lines for MYCN amplification studies and for testing differentiation therapies (e.g., retinoic acid, GD2 antibodies). Glioblastoma cell lines are used for temozolomide resistance studies and for evaluating EGFR inhibitors. Our neuroectodermal and neuroendocrine tumors category supports brain and neuroendocrine cancer research with authenticated, well-characterized cell lines.